Results 121 to 130 of about 57,759 (194)

Pediatric H3 G34-mutant diffuse hemispheric glioma: clinical, imaging and molecular prognostic factors, MGMT expression, and temozolomide response. [PDF]

Acta Neuropathol
Tlais D, Zhang Q, Roach JT, Tinkle CL, Lin T, Li X, Mostafa A, Moreira DC, McNall-Knapp RY, Rush SZ, Le BH, Sinno S, Ramnarayan A, Ginn KF, Partap S, Onar-Thomas A, Furtado LV, Bag AK, Chiang J.   +18 more
europepmc   +1 more source

Leptomeningeal metastasis from large-cell neuroendocrine carcinoma of the cervix: a case report and literature review. [PDF]

Front Oncol
Xu P, Wang ZJ, Dang XM, Zhu BY, Zheng ZC.   +4 more
europepmc   +1 more source

Characterization and clinical implications of CpG island methylator phenotypes of resistant tumors. [PDF]

Clin Epigenetics
Hou F, Zhou X, Huang YE, Liu H, Yuan M, Chen J, Wang Q, Jiang W.   +7 more
europepmc   +1 more source

Retraction Note: Glioblastoma stem cell (GSC)-derived PD-L1-containing exosomes activates AMPK/ULK1 pathway mediated autophagy to increase temozolomide-resistance in glioblastoma. [PDF]

Cell Biosci
Zheng Y, Liu L, Wang Y, Xiao S, Mai R, Zhu Z, Cao Y.   +6 more
europepmc   +1 more source

In vitro assays as a tool to personalize treatment in central nervous system tumors: a systematic literature review. [PDF]

Clin Exp Med
Offi M, Buccarelli M, Chiesa S, Mazzarella C, Falchetti ML, Ceccarelli GM, Di Monaco G, Cocilovo FM, Taglialatela M, Shetty S, Olivi A, Lauretti L, Pallini R, Ricci-Vitiani L, D'Alessandris QG.   +14 more
europepmc   +1 more source

Recurrent hematological toxicity after second-line treatment in patients with glioblastoma: indication of a potential predisposition. [PDF]

Oncologist
van Hout L, van den Elzen FEL, de Jong Z, Grun N, Broen MPG, Bartelink I, Bruynzeel AME, Lagerwaard FJ, Buter J, Vandertop WP, Westerman BA, Lissenberg-Witte BI, Kouwenhoven MCM.   +12 more
europepmc   +1 more source

Protocol for neuro-oncology anywhere 242: Pilot study evaluating telehealth and in-person assessments in patients with glioma receiving oral chemotherapy. [PDF]

Contemp Clin Trials Commun
Sener U, Galloway T, Neth B, Uhm J, Kizilbash SH, Campian JL, Caron S, Breen WG, Lehrer E, Golembiewski E, Schultz S, Hughes H, Steinmetz S, Geyer S, Mead-Harvey C, Huebert C, Tauer W, Mason C, Burns TC, Pritchett J, Haddad T.   +20 more
europepmc   +1 more source

Adjuvant chemoradiotherapy with procarbazine, lomustine, and vincristine (PCV) or temozolomide for 1p/19q Co-deleted anaplastic oligodendroglioma: a systematic review and network meta-analysis. [PDF]

BMC Cancer
Santos MDC, Rodrigues NMV, Gibram F, Gouhie FA, Campos ACP, de Assis DV, Formentin C, Feher O, de Souza E Silva ARN, Hanna SA, Chung C, Barbosa CC, Moraes FY, Maldaun MVC.   +13 more
europepmc   +1 more source

Ivosidenib treatment in IDH-mutant WHO grade 4 astrocytomas: illustrative case. [PDF]

J Neurosurg Case Lessons
Adjei BO, Renterghem JP, Hayes Meizoso C, Daci R, Mietus CJ, Amenta PS, Johnson MD, Cachia D.   +7 more
europepmc   +1 more source

Alterations of the tumor microenvironment (TME) by exploratory gene expression analysis in recurrent glioblastoma following apatinib in combination with temozolomide. [PDF]

Biochem Biophys Rep
Ge J, Li C, Xue F, Zhao C, Kong C, Qi S, Duan Q, Zhang Q, Zhang J.   +8 more
europepmc   +1 more source